Events & Presentations

Investors

Events & Presentations

Upcoming Events
Date Event Details Remind Me
Mar 26, 2019 4:35 PM EDT
Oligonucleotide & Precision Therapeutics (OPT) Congress
James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “siRNA Clinical Development Based on the TRiMTM Platform”
Cambridge, MA
Mar 27 - Mar 30, 2019
CSHL Meeting: RNA & Oligonucleotide Therapeutics
Dr. Hamilton will deliver an oral presentation titled, “Cardiovascular and lipid disorders - A next frontier for TRiMTM RNAi”
Cold Spring Harbor, NY
Apr 3, 2019 8:00 AM EDT
AACR Annual Meeting 2019
So Wong, Ph.D., Arrowhead’s director of oncology, will deliver a poster presentation titled, “Optimizing the potency and dosing design for ARO-HIF2: An RNAi therapeutic for clear cell renal cell carcinoma”
Apr 10, 2019
The EASL International Liver Congress 2019

Oral Presentation:
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg <100 IU/mL threshold

  • Presentation Reference: PS-080
  • Session: Parallel session: Hepatitis B - drug development
  • Date and Time: April 12, 2019 at 5:45 p.m. CET
  • Authors: Man-Fung Yuen, et al.

Poster Presentation:
Reduction of hepatic Z-alpha1 antitrypsin by RNA interference (RNAi) prevents and reverses liver disease including hepatic mitochondrial injury in the PiZ mouse model

  • Presentation Reference: FRI-446
  • Session: Poster: Rare liver diseases (including pediatric and genetic)
  • Session Date and Time: April 12, 2019 from 9 a.m. to 5 p.m. CET
  • Authors: Christine Wooddell, et al.
Archived Events
Date Event Details
Jun 6, 2018 3:30 PM EDT
Jefferies 2018 Global Healthcare Conference
New York, NY
Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview
Jun 6, 2018 5:55 PM CEST
41st European Cystic Fibrosis Conference
Belgrade, Serbia
Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled,“Targeting aENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”
May 21, 2018 9:15 AM PDT
American Thoracic Society (ATS) 2018 International Conference
San Diego
May 10, 2018 4:15 PM PDT
Vascular Discovery: From Genes to Medicine – Scientific Sessions 2018
San Francisco
May 8, 2018 4:30 PM EDT
Arrowhead Fiscal 2018 Second Quarter Results
Apr 25, 2018 4:00 PM EDT
World Orphan Drug Congress USA 2018
Apr 12 - Apr 14, 2018
The EASL International Liver Congress™ 2018

Oral Presentations:

Development of subcutaneously administered RNAi therapeutic ARO-HBV for chronic hepatitis B virus infection

  • Presentation Reference: PS-030
  • Session: Parallel session: Parallel session: HBV Cure: Pre-clinical studies
  • Date and Time: April 12, 2018 at 5:15 p.m. CET
  • Authors: Christine Wooddell, et al.

ARO-AAT, a subcutaneous RNAi-based therapeutic for alpha-1 antitrypsin-related liver disease, demonstrates liver exposure-response and efficacy in preclinical studies

  • Presentation Reference: PS-147
  • Session: Parallel session: Clinical developments in metabolic and rare disease
  • Date and Time: April 14, 2018 at 9:15 a.m. CET
  • Authors: Christine Wooddell, et al.

Poster Presentation:

RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV

  • Presentation Reference: FRI-362
  • Session: Viral hepatitis B/D: Therapy
  • Session Date and Time: April 13, 2018 from 9 a.m. to 5 p.m. CET
  • Authors: Man-Fung Yuen, et al.
Mar 29, 2018
American Society for Clinical Pharmacology & Therapeutics 2018 Annual Meeting
Mar 22, 2018
American Society for Clinical Pharmacology & Therapeutics 2018 Annual Meeting
Mar 13, 2018 1:35 PM EDT
Barclays Global Healthcare Conference 2018
Miami